Estuary Launches With $103M for Kidney Disease Gene Therapies

· Health · United States

Estuary Biotherapeutics launched with $103 million to advance two preclinical gene therapy candidates for the most common type of inherited kidney disease, with the Series A round led by RA Capital and backing from Biogen. The medicines are designed to treat an inherited kidney disorder known as ADPKD. The financing gives the company runway to move its programs toward clinical testing in a disease area with substantial unmet need and few genetic treatment options. The launch adds to a recent wave of well-funded gene therapy startups targeting organ-specific conditions, as investors continue to place bets on genetic medicines beyond the liver and more established targets.

Why it matters：A sizable Series A for kidney gene therapy shows investors funding genetic medicines outside the liver, and if the preclinical programs succeed they could open a new treatment avenue for a common inherited kidney disease.

Key points

  • Estuary Biotherapeutics launched with $103 million to advance two preclinical gene therapy candidates.
  • The Series A was led by RA Capital, with Biogen backing the company.
  • The therapies target ADPKD, the most common type of inherited kidney disease.

Sources (original reporting)

More stories from this day